Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05154123 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) | PHASE1 | COMPLETED | 29 | — | — | Nov 16, 2021 | Dec 23, 2021 | Feb 25, 2022 | 1 | Canada |
Maximum plasma concentration (Cmax)
Area under the concentration-time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| AT-527 + rosuvastatin (simultaneous) n=14 | EXPERIMENTAL | - |
| AT-527 + rosuvastatin (staggered) n=14 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Drug: AT-527 + rosuvastatin | DRUG | * Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single dose of AT-527 and rosuvastatin will be co-administered. |
| AT-527 + rosuvastatin | DRUG | * Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later) |
Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg...